Combating antimicrobial resistance (AMR)
There are compelling economic and health arguments for addressing AMR. Simply stated, the cost of treating tuberculosis is minuscule compared to treating somebody with drug-resistance. We need rapid diagnostics that can quickly diagnose whether the person has a viral, bacterial or resistant infection. If I was an investor today, I would look at companion diagnostics for antibiotics in development. AMR requires a multi-faceted approach but diagnostics is the door that can really open up the potential to reverse the AMR threat. We need governments, industry, investors, and healthcare systems to attack it. Because all of us need to be resistance fighters.